Edit this postWhy Is Jefferies Bullish On Mankind Pharma Over Dr. Reddy's And Cipla?
Global brokerage Jefferies has reiterated its differentiated stance on the Indian pharmaceutical sector by maintaining a bullish view on Mankind Pharma while remaining cautious on Dr. Reddy's Laboratories and Cipla. The brokerage believes valuation comfort and improving business momentum favour Mankind, whereas upside in Dr. Reddy's and Cipla appears relatively limited.
Jefferies' Latest Ratings
- Mankind Pharma: Buy | Target Price: ₹3,000
- Dr. Reddy's Laboratories: Underperform | Target Price: ₹1,040
- Cipla: Underperform | Target Price: ₹1,120
Stay updated with sector-leading research through our Nifty Tip.
Why Jefferies Prefers Mankind Pharma
According to Jefferies, even under a conservative or "rainy-day" scenario, Mankind Pharma's downside is limited to around 11%. The brokerage believes this downside carries a relatively low probability as early signs of an operational turnaround have already started emerging.
The improving business outlook, combined with attractive risk-reward, makes Mankind Pharma the brokerage's preferred pick within the sector.
Why Dr. Reddy's Faces Limited Upside
Jefferies believes Dr. Reddy's offers only about 14% potential upside even under optimistic assumptions. The brokerage feels that much of the positive outlook is already reflected in the current valuation, leaving relatively limited scope for meaningful re-rating.
Track market opportunities with our BankNifty Tip.
Why Jefferies Remains Cautious On Cipla
The brokerage estimates Cipla's potential upside at around 12%. Jefferies notes that a stronger bullish case depends largely on timely regulatory approval of two important products in the United States, an outcome it considers unlikely within its current expectations.
Key Investment Takeaways
- Mankind Pharma continues to offer the most attractive risk-reward profile.
- Dr. Reddy's valuation leaves limited room for further upside.
- Cipla's future performance depends significantly on US regulatory approvals.
- Execution and earnings delivery remain key monitorable factors across the pharma sector.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that brokerage preference is increasingly shifting toward companies offering favourable risk-reward rather than simply strong historical performance. Investors should evaluate earnings visibility, valuation comfort and business execution before making investment decisions instead of relying solely on target prices.
Related Queries
- Why is Jefferies bullish on Mankind Pharma?
- Why has Jefferies downgraded Dr. Reddy's?
- What is Jefferies' target price for Cipla?
- Which pharma stock does Jefferies prefer?
- Is Mankind Pharma a better buy than Cipla?
Disclaimer: Brokerage reports represent the views of the respective research firm and are not investment recommendations by Indian-Share-Tips.com. Investors should conduct their own research before making investment decisions.
